Friday, 16 October 2026European Markets

KMC PROPERTIES Stock 19.75% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with KMC PROPERTIES (KMCP.OL) jumping 19.75% to kr1.94 on Friday, after five sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 1.35% to kr1,434.43, after two consecutive sessions in a row of gains, on what was an all-around bullish trend exchanging session today.

KMC PROPERTIES's last close was kr1.62, 79.7% under its 52-week high of kr7.98.

About KMC PROPERTIES

KMC Properties ASA, a real estate company, owns and operates industrial and logistics properties. The company owns properties in the Nordics and the Netherlands in Moscow, Russia. KMC Properties ASA was incorporated in 2007 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, KMC PROPERTIES has a trailing twelve months EPS of kr-0.09.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -0.7%.

More news about KMC PROPERTIES (KMCP.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com